Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
As of Jun. 2026, Cowealth Medical Holding Co has a Sloan Ratio of 1.95%, indicating the company is in the safe zone and there is no funny business with accruals.
Cowealth Medical Holding Co (ROCO:4745) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Jun. 2026, Cowealth Medical Holding Co has a Sloan Ratio of 1.95%, indicating the company is in the safe zone and there is no funny business with accruals.
Cowealth Medical Holding Co Sloan Ratio % Related Terms
Cowealth Medical Holding Co Sloan Ratio % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4745 vs ABT, SYK, MDT: Sloan Ratio % Comparison
For the Medical Devices subindustry, Cowealth Medical Holding Co's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cowealth Medical Holding Co Sloan Ratio % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cowealth Medical Holding Co's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Cowealth Medical Holding Co's Sloan Ratio % falls into.
Cowealth Medical Holding Co Sloan Ratio % Calculation
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Cowealth Medical Holding Co's Net Income for the trailing twelve months (TTM) ended in Jun. 2026 was -31.87 (Sep. 2025 ) + -160.682 (Dec. 2025 ) + -31.157 (Mar. 2026 ) + -24.623 (Jun. 2026 ) = NT$-248 Mil.
Cowealth Medical Holding Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was -85.864 (Sep. 2025 ) + -481.14 (Dec. 2025 ) + -342.748 (Mar. 2026 ) + 350.71 (Jun. 2026 ) = NT$-559 Mil.
Cowealth Medical Holding Co's Cash Flow from Investing for the trailing twelve months (TTM) ended in Jun. 2026 was 210.295 (Sep. 2025 ) + 175.653 (Dec. 2025 ) + -72.765 (Mar. 2026 ) + -142.703 (Jun. 2026 ) = NT$170 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cowealth Medical Holding Co (ROCO:4745) has a Sloan Ratio % of 1.95% as of Jun. 2026. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Cowealth Medical Holding Co and its competitors.
Is Cowealth Medical Holding Co's Sloan Ratio % too high?
Cowealth Medical Holding Co's current Sloan Ratio % is 1.95%. Overall, Cowealth Medical Holding Co has a GF Score™ of 53/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cowealth Medical Holding Co's Sloan Ratio % compare to ABT and SYK?
Cowealth Medical Holding Co's Sloan Ratio % of 1.95% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Sloan Ratio % for a Medical Devices & Instruments company?
A good Sloan Ratio % depends on the Medical Devices & Instruments industry context. However, Sloan Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Sloan Ratio % mean?
A high Sloan Ratio % can signal that a stock is expensive relative to its fundamentals. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Cowealth Medical Holding Co and its competitors. Cowealth Medical Holding Co's current Sloan Ratio % is 1.95%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cowealth Medical Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Cowealth Medical Holding Co (ROCO:4745) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$14.10, compared to a current price of NT$11.70 — trading 17% below its estimated fair value. The current Sloan Ratio % is 1.95%. Cowealth Medical Holding Co's overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Sloan Ratio % calculated?
Sloan Ratio % is calculated from a company's financial statements. For Cowealth Medical Holding Co (ROCO:4745), the current Sloan Ratio % is 1.95% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cowealth Medical Holding Co (ROCO:4745) Overvalued in 2026?
Based on GuruFocus' analysis, Cowealth Medical Holding Co stock appears to be undervalued.
The current stock price of NT$11.70 is trading 17% below its estimated GF Value™ of NT$14.10.
GuruFocus considers Cowealth Medical Holding Co to be Modestly Undervalued.
Key valuation signals for ROCO:4745:
Sloan Ratio %: 1.95%
GF Value™: NT$14.10 vs. price of NT$11.70 (17% below fair value)
No single metric tells the full story. See the ROCO:4745 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cowealth Medical Holding Co Ltd is mainly involved in trading medical equipment, reagents, and spare parts. Its wide range of solutions includes refined management services tailored for in-vitro diagnostic products, reagents, and consumables, an integrated platform designed for decision-making and analysis, commercialization of achievements in medical science and technology, a Multi-Channel Coaxial Time Audio Video Imaging Platform (MCCTAVIP), and an AI-assisted system for clinical diagnosis. The Group has two reportable segments: Segment A, which generates maximum revenue and sells equipment, and Segment B, which sells reagents and others. Geographically, it generates maximum revenue from China and Hong Kong, and the rest from Taiwan.
53GF Score
Get the complete analysis for ROCO:4745
Sloan Ratio % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4745 has been successfully added to your 
